CellaVision has through its wholly owned subsidiary CellaVision Inc., performed a strategic acquisition by acquiring the assets and intellectual property of Triangle Imaging Inc. (TII) from Triangle Biomedical Sciences Inc. (TBS). TII, formerly known as IMI, Intelligent Medical Imaging Inc., has until now been CellaVision's leading competitor in the digital analysis of white blood cells. TII is based in Jupiter, Florida where CellaVision Inc. will now have its base.
CellaVision will now have direct access to the automated microscope MICRO21®, including technology, inventory, existing customers and also a detailed market analysis of potential customers in the U.S. market. The new CellaVision team will provide direct and immediate access to the American market and also bring their substantial experience and knowledge.
"Through the acquisition, we will gain much quicker access to the U.S. market for our instrument DiffMaster , which will be introduced in the U.S. next year. At the same time, sales of the MICRO21® will continue. The two instruments complement each other very well and they will be positioned accordingly at diversified segments of the market", says Yvonne Mårtensson, President and CEO of CellaVision AB.
The establishment of a wholly owned subsidiary in the U.S. will facilitate and accelerate the process of establishing American partnerships. Having direct access to an established support network within the country will be a strong key factor in coming discussions with potential partners for sales and distribution of the CellaVision products.
"The experience of TII combined with advanced software engineering competence of CellaVision will definitely be a winning concept", says Yvonne Mårtensson.
- Last November, Sysmex signed a Letter of Intent regarding distribution of CellaVision's products in selected countries, starting with Germany.
- CellaVision recently received FDA approval (from the Food and Drug Administration in the USA) to sell DiffMaster(TM) Octavia in the U.S.
- CellaVision has sold its first DiffMaster(TM). Malmö University Hospital (MAS) has decided to install CellaVision's system for digital image processing of blood cells at its clinical chemical laboratory. The laboratory will become a strategic partner to CellaVision for further development of the system.
- During the spring of 2001 CellaVision reached an agreement concerning distribution of CellaVision's product DiffMaster(TM) on the German market.